Filing Details

Accession Number:
0001209191-23-052030
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-04 17:07:25
Reporting Period:
2023-10-02
Accepted Time:
2023-10-04 17:07:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
827871 Eagle Pharmaceuticals Inc. EGRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1469124 Scott Tarriff C/O Eagle Pharmaceuticals, Inc.
50 Tice Blvd., Suite 315
Woodcliff Lake NJ 07677
Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-10-02 9,511 $15.23 577,800 No 4 S Direct
Common Stock Disposition 2023-10-03 10,024 $14.41 567,776 No 4 S Direct
Common Stock Disposition 2023-10-03 710 $15.11 567,066 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 992,623 Indirect By Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016
Footnotes
  1. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.035 to $15.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.09 to $15.05 inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.18 inclusive.
  5. The shares are held by the Trust for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of the shares, except to any pecuniary interest therein, if any.